Insulin growth factor binding proteins as therapeutic targets in type 2 diabetes

2013 ◽  
Vol 18 (2) ◽  
pp. 209-224 ◽  
Author(s):  
Rikke Hjortebjerg ◽  
Allan Flyvbjerg ◽  
Jan Frystyk
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Binding Proteins ◽  
Therapeutic Targets ◽  
Factor Binding ◽  
Insulin Growth Factor

scholarly journals Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance

2021 ◽  
Vol 22 (3) ◽  
pp. 1133
Author(s):  
Hatim Boughanem ◽  
Elena M. Yubero-Serrano ◽  
José López-Miranda ◽  
Francisco J. Tinahones ◽  
Manuel Macias-Gonzalez
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Growth Factor ◽  
Therapeutic Target ◽  
Binding Protein ◽  
Factor Binding ◽  
Insulin Growth Factor

Evidence from observational and in vitro studies suggests that insulin growth-factor-binding protein type 2 (IGFBP2) is a promising protein in non-communicable diseases, such as obesity, insulin resistance, metabolic syndrome, or type 2 diabetes. Accordingly, great efforts have been carried out to explore the role of IGFBP2 in obesity state and insulin-related diseases, which it is typically found decreased. However, the physiological pathways have not been explored yet, and the relevance of IGFBP2 as an important pathway integrator of metabolic disorders is still unknown. Here, we review and discuss the molecular structure of IGFBP2 as the first element of regulating the expression of IGFBP2. We highlight an update of the association between low serum IGFBP2 and an increased risk of obesity, type 2 diabetes, metabolic syndrome, and low insulin sensitivity. We hypothesize mechanisms of IGFBP2 on the development of obesity and insulin resistance in an insulin-independent manner, which meant that could be evaluated as a therapeutic target. Finally, we cover the most interesting lifestyle modifications that regulate IGFBP2, since lifestyle factors (diet and/or physical activity) are associated with important variations in serum IGFBP2.

scholarly journals Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men

Diabetologia ◽  
2008 ◽  
Vol 51 (7) ◽  
pp. 1135-1145 ◽  
Author(s):  
M. S. Lewitt ◽  
A. Hilding ◽  
C.-G. Östenson ◽  
S. Efendic ◽  
K. Brismar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Middle Aged ◽  
Factor Binding

scholarly journals Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 68 (1) ◽  
pp. 188-197 ◽  
Author(s):  
Clemens Wittenbecher ◽  
Meriem Ouni ◽  
Olga Kuxhaus ◽  
Markus Jähnert ◽  
Pascal Gottmann ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Factor Binding

scholarly journals Insulin-like growth factor I, binding proteins -1 and -3, risk of type 2 diabetes and macronutrient intakes in men

2019 ◽  
Vol 121 (8) ◽  
pp. 938-944
Author(s):  
Minna E. Similä ◽  
Jukka P. Kontto ◽  
Jarmo Virtamo ◽  
Katja A. Hätönen ◽  
Liisa M. Valsta ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Binding Proteins ◽  
Conditional Logistic Regression ◽  
Intervention Group ◽  
Diabetes Risk ◽  
Insulin Like Growth Factor ◽  
Baseline Serum ◽  
Igf I

AbstractThe insulin-like growth factor (IGF) axis may be involved in the development of type 2 diabetes. We examined the associations of IGF-I and IGF binding proteins (IGFBP)-1 and -3 with diabetes risk and evaluated macronutrient intakes related to the observed associations. In a nested case–control study of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of Finnish male smokers aged 50–69 years, the IGF variables were measured from baseline serum samples for a random sample of 310 men with diabetes diagnosed during a 12-year follow-up and for 310 controls matched by age, recruitment day and intervention group. Diet at baseline was assessed using a validated FFQ. The associations of IGF proteins with diabetes risk were estimated using conditional logistic regression and the associations with macronutrient intakes using linear regression. IGF-I and IGFBP-3 were not associated with the incidence of diabetes. Higher IGFBP-1 was associated with lower diabetes risk in an unadjusted crude model (OR 0·25; 95 % CI 0·15, 0·42 in the highest quartile compared with the lowest), but not after adjustment for BMI (corresponding OR 0·76; 95 % CI 0·41, 1·40). Intakes of carbohydrates, plant protein and milk protein associated positively and intake of meat protein and fat negatively with IGFBP-1 (P<0·005). IGFBP-1 was inversely associated with diabetes risk, but the association was substantially dependent on BMI. The associations between macronutrient intakes and IGFBP-1 may reflect influences of nutrients or foods on insulin concentrations.

scholarly journals Characterization and Expression Analysis of Insulin Growth Factor Binding Proteins (IGFBPs) in Pacific White Shrimp Litopenaeus vannamei

2021 ◽  
Vol 22 (3) ◽  
pp. 1056
Author(s):  
Ying Pang ◽  
Xiaojun Zhang ◽  
Jianbo Yuan ◽  
Xiaoxi Zhang ◽  
Jianhai Xiang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Litopenaeus Vannamei ◽  
Binding Proteins ◽  
Developmental Stages ◽  
Expression Profiles ◽  
Serine Proteinase ◽  
Pacific White Shrimp ◽  
White Shrimp ◽  
Factor Binding ◽  
Insulin Growth Factor

The insulin signaling (IIS) pathway plays an important role in the metabolism, growth, development, reproduction, and longevity of an organism. As a key member of the IIS pathway, insulin-like growth factor binding proteins (IGFBPs) are widely distributed a family in invertebrates and vertebrates that are critical in various aspects of physiology. As an important mariculture species, the growth of Pacific white shrimp, Litopenaeus vannamei, is one of the most concerning characteristics in this area of study. In this study, we identified three IGFBP genes in the genome of L. vannamei and analyzed their gene structures, phylogenetics, and expression profiles. LvIGFBP1 was found to contain three domains (the insulin growth factor binding (IB) domain, the Kazal-type serine proteinase inhibitor (Kazal) domain, and the immunoglobulin C-2 (IGc2) domain), while LvIGFBP2 and LvIGFBP3 only contained a single IB domain. LvIGFBP1 exhibited high expression in most tissues and different developmental stages, while LvIGFBP2 and LvIGFBP3 were only slightly expressed in hemocytes. The RNA interference of LvIGFBP1 resulted in a significantly smaller increment of body weight than that of control groups. These results will improve our understanding of the conservative structure and function of IGFBPs and show potential applications for the growth of shrimp.

Sign in / Sign up

Export Citation Format

Share Document